Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure. Propose adaptations to HACOR score based on the "state of art" of COVID-19
Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure. Propose adaptations to HACOR score based on the "state of art" of COVID-19 \- this adaptations may include radiologic aggravation and monitoring of CRF, ferritin, LDH, d-dimers, NT-proBNP, troponin I, GOT, GPT, blood count
Study Type
OBSERVATIONAL
Enrollment
100
Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely: * lymphopenia * thrombocytopenia * CRP * ferritin * LDH * troponin I * NT-ProBNP * Liver enzymes * D-dimers * radiologic aggravation " 1 day and 1 week after starting NIV or CPAP
Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
Hospital General Universitario Morales Meseguer
Murcia, Spain
RECRUITINGHACOR score efficacy
Analyze if HACOR score is effective in predicting nonivasive ventilation failure in COVID-19 associated respiratory failure
Time frame: 1 hour after initation of CPAP or NIV
HACOR score addaptation
Analyze the role of possible variables to be added to HACOR score in order to improve efficay in COVID-19 patients
Time frame: 1 - 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.